Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05535244 · ClinicalTrials.gov registry record · Phase 1
A Study Evaluating the Efficacy and Safety of Cevostamab in Prior B Cell Maturation Antigen (BCMA)-Exposed Participants With Relapsed/Refractory Multiple Myeloma
A Phase 1 study of Multiple Myeloma, sponsored by Hoffmann-La Roche.
- Active
- Registry status
- Phase 1
- Development phase
- 90
- Enrollment target
- 20
- Study locations
NCT05535244: Active Phase 1 study of Multiple Myeloma, sponsored by Hoffmann-La Roche.
NCT05535244 is a Phase 1 study of Multiple Myeloma that is active but no longer recruiting, run by Hoffmann-La Roche. The registered enrollment target is 90 participants, below the 547-participant average among 438 other Multiple Myeloma trials with a reported enrollment target (84% lower). The trial reports 20 study locations across 11 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05535244, a Phase 1 study of Multiple Myeloma, is active but no longer recruiting, sponsored by Hoffmann-La Roche.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 1
- Development phase
- 90 participants
- Enrollment target
- 20
- Study locations
Study Summary
This study will evaluate the efficacy, safety, and pharmacokinetics of cevostamab in participants with relapsed or refractory multiple myeloma (R/R MM) via intravenous (IV) infusion.
Conditions Studied
Interventions
- DRUG Tocilizumab
- DRUG Cevostamab
Study Locations (20)
Other
- UZ Leuven Gasthuisberg - Leuven
- CHU NANTES - Hôtel Dieu - Nantes
- APHP - Hospital Saint Louis - Paris
- CHU de Poitiers - La Miletrie - Poitiers
- Klinik der Uni zu Köln - Cologne
- Universitätsklinikum Hamburg-Eppendorf Onkologisches Zentrum Medizinische Klinik II - Hamburg
- Universitätsklinikum Würzburg - Würzburg
- Hadassah Ein Karem Hospital - Jerusalem
- Sheba Medical Center - Ramat Gan
- Sourasky Medical Centre - Tel Aviv
Colorado
- University of Colorado - Aurora
Florida
- Mayo Clinic-Jacksonville - Jacksonville
Maryland
- University of Maryland Greenebaum Cancer Center - Baltimore
Massachusetts
- Dana Farber Cancer Institute - Boston
Minnesota
- Mayo Clinic - Rochester - Rochester
New York
- Memorial Sloan Kettering Cancer Center - New York
Tennessee
- Tennessee Oncology - Nashville - Nashville
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 90 participants |
| Start Date | 2022-10-17 |
| Est. Completion | 2027-02-26 |
| Phase | Phase 1 |
What the registry record for NCT05535244 still lists
NCT05535244 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 90 participants, a relatively small participant target, below the 547-participant average among 438 other Multiple Myeloma trials with a reported enrollment target (84% lower).
The record links to 1 condition, with Multiple Myeloma appearing as the primary indexed condition, and to 2 interventions - of which Tocilizumab is the first listed.
NCT05535244 names 20 study sites across 11 states, led by Other, Colorado, Florida.
Frequently Asked Questions
What is clinical trial NCT05535244 about?
NCT05535244 is a clinical study titled "A Study Evaluating the Efficacy and Safety of Cevostamab in Prior B Cell Maturation Antigen (BCMA)-Exposed Participants With Relapsed/Refractory Multiple Myeloma". This study will evaluate the efficacy, safety, and pharmacokinetics of cevostamab in participants with relapsed or refractory multiple myeloma (R/R MM) via intravenous (IV) infusion.
What is the current status of trial NCT05535244?
This trial is currently active not recruiting. It is a Phase 1 study. The enrollment target is 90 participants. The study started on 2022-10-17. Estimated completion is 2027-02-26.
What conditions does trial NCT05535244 study?
This clinical trial studies the following conditions: Multiple Myeloma.
What interventions are being tested in trial NCT05535244?
The interventions under investigation include: Tocilizumab (DRUG), Cevostamab (DRUG).
Who is sponsoring clinical trial NCT05535244?
This trial is sponsored by Hoffmann-La Roche, which has 909 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05535244 being conducted?
This trial has 20 study locations across Colorado, Florida, Maryland, Massachusetts, Minnesota. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Multiple Myeloma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT05535244's enrollment target sits among peer trials
90 184th of 438 higher than 250 of 438 other Multiple Myeloma trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Multiple Myeloma trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
A Study to Investigate the Safety and Efficacy of Belantamab for the Treatment of Multiple Myeloma When Used as Monotherapy and in Combination Treatments
RECRUITING · Phase 1
-
TriPRIL CAR T Cells in Multiple Myeloma
RECRUITING · Phase 1
-
A Study to Assess Adverse Events and Change in Disease Activity of Oral ABBV-453 Alone or in Combination With Subcutaneous and/or Oral Antimyeloma Agents in Adult Participants With Multiple Myeloma (MM)
RECRUITING · Phase 1
-
AZD0305 as Monotherapy or in Combination With Anticancer Agents in Participants With Relapsed/Refractory Multiple Myeloma
RECRUITING · Phase 1
-
Study of Carfilzomib, Lenalidomide, Dexamethasone and Belantamab Mafodotin in Multiple Myeloma
RECRUITING · Phase 1
-
CRISPR Delivered Anti-BCMA Car-T Therapy for Relapsed or Refractory Multiple Myeloma
RECRUITING · Phase 1
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02521311 · 90 participants · Phase 2
Assessment of Clemastine Fumarate as a Remyelinating Agent in Acute Optic Neuritis (ReCOVER)
- NCT02939573 · 90 participants · Phase 2
A Randomized Multicenter Study for Isolated Skin Vasculitis
- NCT03128879 · 90 participants · Phase 2
Venetoclax With Ibrutinib or Acalabrutinib in Pts. With High-risk CLL
- NCT03184038 · 90 participants · NA
Neurocognition in Patients With Multiple Brain Metastases Treated With Radiosurgery
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI